Agoracom: Small Cap Investment - Zenith Epigenetics

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

narmac

Rank: Vice President [?]

Points: 3995 [?]

Votes: 36 Score: 3.0 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Feb. 06, 2019 FMV ZENE!

posted on Feb 07, 2019 12:11PM

Management’s Estimate of Fair Value of Common Shares February 6, 2019 To whom it may concern, Management’s estimate of the fair value of the common shares of Zenith Capital Corp. for financial reporting purposes was USD $0.689 per share as at October 31, 2018. If you require further information, please contact Sarah Zapotichny at (403) 254-9252 ex. 875. (signed) “Brad Cann”Brad Cann, CA, CBVChief Financial Officer Zenith Capital Corp.